PHI expands into Australia and respiratory research

In April Phase Holographic Imaging (PHI) had outstanding orders of approximately 2 MSEK, consisting of 13 HoloMonitor M4 units and 15 orders for the recently launched motorized stage. A portion of these units have now been delivered. Among others, a HoloMonitor M4 with motorized stage has been delivered to one of the leading institutes for respiratory research in Australia – the Woolcock Institute of Medical Research.

To improve the understanding of the mechanisms behind asthma the Respiratory Cellular and Molecular Biology Group will measure volume changes in respiratory muscle cells using PHI’s HoloMonitor technology. The ability to effortlessly measure changes in cell volume is one of the unique and innovative advantages of HoloMonitor technology.

“We see a limited value in reporting individual orders and deliveries that lack strategic value to our investors. However, this installation is of strategic value as it is our first instrument on the Australian continent. Additionally, the order opens up a new market for us – respiratory research”, says Peter Egelberg, CEO of PHI.